Last reviewed · How we verify
Mandated back ground therapy
Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles.
Metformin works by decreasing glucose production in the liver, increasing insulin sensitivity, and enhancing glucose uptake in muscles. Used for Type 2 diabetes, Polycystic ovary syndrome (PCOS).
At a glance
| Generic name | Mandated back ground therapy |
|---|---|
| Sponsor | Sanofi |
| Drug class | biguanide |
| Modality | Small molecule |
| Therapeutic area | Diabetes |
| Phase | FDA-approved |
Mechanism of action
Metformin acts by inhibiting the mitochondrial respiratory chain complex I, which decreases hepatic glucose production. It also increases insulin sensitivity by enhancing glucose uptake in muscles and adipose tissue. Additionally, metformin decreases glucose absorption from the gut.
Approved indications
- Type 2 diabetes
- Polycystic ovary syndrome (PCOS)
Common side effects
- Gastrointestinal upset
- Lactic acidosis
Key clinical trials
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Mandated back ground therapy CI brief — competitive landscape report
- Mandated back ground therapy updates RSS · CI watch RSS
- Sanofi portfolio CI